Oppenheimer reaffirmed their hold rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Thursday.

Several other research firms have also commented on TEVA. BTIG Research raised shares of Teva Pharmaceutical Industries from a sell rating to a neutral rating in a research report on Monday, September 17th. Citigroup set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a research report on Thursday, May 31st. Barclays set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Thursday, August 2nd. Mizuho reaffirmed a buy rating and set a $27.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 2nd. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Friday, July 13th. Seven analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $21.11.

Shares of NYSE:TEVA opened at $24.36 on Thursday. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $25.96. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $24.77 billion, a price-to-earnings ratio of 6.20, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The business had revenue of $4.70 billion during the quarter, compared to analyst estimates of $4.75 billion. During the same quarter in the previous year, the firm earned $1.02 EPS. Teva Pharmaceutical Industries’s revenue was down 17.8% on a year-over-year basis. sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.67 earnings per share for the current year.

In other news, EVP Sven Dethlefs bought 2,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 3rd. The stock was bought at an average cost of $21.92 per share, with a total value of $43,840.00. Following the acquisition, the executive vice president now owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at $56,334.96. The disclosure for this sale can be found here. Insiders sold a total of 10,350 shares of company stock valued at $239,430 over the last three months. 0.43% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Global Financial Private Capital LLC boosted its stake in Teva Pharmaceutical Industries by 92.2% in the 2nd quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock worth $575,000 after purchasing an additional 11,335 shares during the period. Sei Investments Co. boosted its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock worth $3,946,000 after purchasing an additional 34,305 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Teva Pharmaceutical Industries by 553.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock worth $544,000 after purchasing an additional 18,938 shares during the period. Toronto Dominion Bank bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $669,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 25.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 83,473 shares of the company’s stock worth $2,030,000 after purchasing an additional 16,946 shares during the period. 64.52% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Index Funds

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.